Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis Sicca in Sjögren's syndrome

Samin Hong, Terry Kim, So Hyang Chung, Eung Kweon Kim, Kyoung Yul Seo

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate the prevalence of long-term recurrence after topical nonpreserved methylprednisolone pulse therapy for the treatment of keratoconjunctivitis sicca (KCS) with Sjögren's syndrome. Methods: A total of 106 eyes of 53 Sjögren's syndrome patients were included in the study. All patients were treated with topical nonpreserved 1% methylprednisolone solution. Initial therapy consisted of eyedrops 4 times a day for 2 weeks, and then patients were reevaluated and tapered off the medication every 2 weeks until discontinuation. Tear film breakup time (TBUT), Schirmer test, corneal fluorescein staining, and subjective symptom scores were measured. Additionally, impression cytology of the bulbar conjunctiva was performed. The overall success rates and success period were determined using the Kaplan-Meier survival curve. Results: A reduction in subjective symptoms and fluorescein staining, and an improvement in TBUT and Schirmer test results, was observed after treatment (PF < 0.001). Impression cytology specimens revealed a significantly increased number of periodic acid-Schiff-positive cells after treatment. After the first pulse therapy, mean survival was 56.6 weeks and 11 (20.8%) patients recurred. After the second pulse therapy, mean survival was 72.4 weeks and only 1 patient recurred. No serious complications, including intraocular pressure elevation and cataract formation, were encountered during the entire follow-up period. Conclusions: Topical nonpreserved methylprednisolone pulse therapy proved to be a safe, effective long-term treatment of improving subjective and objective dry eye factors in KCS patients with Sjögren's syndrome.

Original languageEnglish
Pages (from-to)78-82
Number of pages5
JournalJournal of Ocular Pharmacology and Therapeutics
Volume23
Issue number1
DOIs
Publication statusPublished - 2007 Feb 1

Fingerprint

Keratoconjunctivitis Sicca
Methylprednisolone
Recurrence
Therapeutics
Fluorescein
Tears
Cell Biology
Staining and Labeling
Periodic Acid
Survival
Ophthalmic Solutions
Conjunctiva
Kaplan-Meier Estimate
Intraocular Pressure
Cataract

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{f254614d83c341d4a3d49682c8af2ab0,
title = "Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis Sicca in Sj{\"o}gren's syndrome",
abstract = "Background: The aim of this study was to evaluate the prevalence of long-term recurrence after topical nonpreserved methylprednisolone pulse therapy for the treatment of keratoconjunctivitis sicca (KCS) with Sj{\"o}gren's syndrome. Methods: A total of 106 eyes of 53 Sj{\"o}gren's syndrome patients were included in the study. All patients were treated with topical nonpreserved 1{\%} methylprednisolone solution. Initial therapy consisted of eyedrops 4 times a day for 2 weeks, and then patients were reevaluated and tapered off the medication every 2 weeks until discontinuation. Tear film breakup time (TBUT), Schirmer test, corneal fluorescein staining, and subjective symptom scores were measured. Additionally, impression cytology of the bulbar conjunctiva was performed. The overall success rates and success period were determined using the Kaplan-Meier survival curve. Results: A reduction in subjective symptoms and fluorescein staining, and an improvement in TBUT and Schirmer test results, was observed after treatment (PF < 0.001). Impression cytology specimens revealed a significantly increased number of periodic acid-Schiff-positive cells after treatment. After the first pulse therapy, mean survival was 56.6 weeks and 11 (20.8{\%}) patients recurred. After the second pulse therapy, mean survival was 72.4 weeks and only 1 patient recurred. No serious complications, including intraocular pressure elevation and cataract formation, were encountered during the entire follow-up period. Conclusions: Topical nonpreserved methylprednisolone pulse therapy proved to be a safe, effective long-term treatment of improving subjective and objective dry eye factors in KCS patients with Sj{\"o}gren's syndrome.",
author = "Samin Hong and Terry Kim and Chung, {So Hyang} and Kim, {Eung Kweon} and Seo, {Kyoung Yul}",
year = "2007",
month = "2",
day = "1",
doi = "10.1089/jop.2006.0091",
language = "English",
volume = "23",
pages = "78--82",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis Sicca in Sjögren's syndrome. / Hong, Samin; Kim, Terry; Chung, So Hyang; Kim, Eung Kweon; Seo, Kyoung Yul.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 23, No. 1, 01.02.2007, p. 78-82.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis Sicca in Sjögren's syndrome

AU - Hong, Samin

AU - Kim, Terry

AU - Chung, So Hyang

AU - Kim, Eung Kweon

AU - Seo, Kyoung Yul

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Background: The aim of this study was to evaluate the prevalence of long-term recurrence after topical nonpreserved methylprednisolone pulse therapy for the treatment of keratoconjunctivitis sicca (KCS) with Sjögren's syndrome. Methods: A total of 106 eyes of 53 Sjögren's syndrome patients were included in the study. All patients were treated with topical nonpreserved 1% methylprednisolone solution. Initial therapy consisted of eyedrops 4 times a day for 2 weeks, and then patients were reevaluated and tapered off the medication every 2 weeks until discontinuation. Tear film breakup time (TBUT), Schirmer test, corneal fluorescein staining, and subjective symptom scores were measured. Additionally, impression cytology of the bulbar conjunctiva was performed. The overall success rates and success period were determined using the Kaplan-Meier survival curve. Results: A reduction in subjective symptoms and fluorescein staining, and an improvement in TBUT and Schirmer test results, was observed after treatment (PF < 0.001). Impression cytology specimens revealed a significantly increased number of periodic acid-Schiff-positive cells after treatment. After the first pulse therapy, mean survival was 56.6 weeks and 11 (20.8%) patients recurred. After the second pulse therapy, mean survival was 72.4 weeks and only 1 patient recurred. No serious complications, including intraocular pressure elevation and cataract formation, were encountered during the entire follow-up period. Conclusions: Topical nonpreserved methylprednisolone pulse therapy proved to be a safe, effective long-term treatment of improving subjective and objective dry eye factors in KCS patients with Sjögren's syndrome.

AB - Background: The aim of this study was to evaluate the prevalence of long-term recurrence after topical nonpreserved methylprednisolone pulse therapy for the treatment of keratoconjunctivitis sicca (KCS) with Sjögren's syndrome. Methods: A total of 106 eyes of 53 Sjögren's syndrome patients were included in the study. All patients were treated with topical nonpreserved 1% methylprednisolone solution. Initial therapy consisted of eyedrops 4 times a day for 2 weeks, and then patients were reevaluated and tapered off the medication every 2 weeks until discontinuation. Tear film breakup time (TBUT), Schirmer test, corneal fluorescein staining, and subjective symptom scores were measured. Additionally, impression cytology of the bulbar conjunctiva was performed. The overall success rates and success period were determined using the Kaplan-Meier survival curve. Results: A reduction in subjective symptoms and fluorescein staining, and an improvement in TBUT and Schirmer test results, was observed after treatment (PF < 0.001). Impression cytology specimens revealed a significantly increased number of periodic acid-Schiff-positive cells after treatment. After the first pulse therapy, mean survival was 56.6 weeks and 11 (20.8%) patients recurred. After the second pulse therapy, mean survival was 72.4 weeks and only 1 patient recurred. No serious complications, including intraocular pressure elevation and cataract formation, were encountered during the entire follow-up period. Conclusions: Topical nonpreserved methylprednisolone pulse therapy proved to be a safe, effective long-term treatment of improving subjective and objective dry eye factors in KCS patients with Sjögren's syndrome.

UR - http://www.scopus.com/inward/record.url?scp=33947364762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947364762&partnerID=8YFLogxK

U2 - 10.1089/jop.2006.0091

DO - 10.1089/jop.2006.0091

M3 - Article

C2 - 17341155

AN - SCOPUS:33947364762

VL - 23

SP - 78

EP - 82

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 1

ER -